


PHARMACEUTICAL 2023

Savara Inc Rank 130 of 446









PHARMACEUTICAL 2023

Savara Inc Rank 130 of 446



The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Savara Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	128,954
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,867
Liabilities, Non-Current	26,132
Other Assets	10,772
Other Compr. Net Income	-610
Other Expenses	31
Other Liabilities	0
Other Net Income	689
Other Revenues	0
Property and Equipment	51
Research and Development	27,879
Selling, General and Administrative Expense	10,929

Output Variable	Value in 1000 USD
Assets	139,777
Liabilities	31,999
Expenses	38,839
Revenues	0
Stockholders Equity	107,778
Net Income	-38,150
Comprehensive Net Income	-38,455
Economic Capital Ratio	171%

